← Leaderboards
Edward Gomperts
Hillhurst Biopharmaceuticals, Inc.
$8,146,154
Attributed
$14,894,056
Total exposure
14
Grants
14
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3M · FY2015–25$5M$3.8M$2.5M$1.3M$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$14,894,056 · 14
By mechanism
R44$8,380,993 · 3
R41$2,449,606 · 6
UG3$2,111,258 · 1
R43$1,224,088 · 3
UH3$728,111 · 1
Top collaborators
- Leo E Otterbein10 shared
- John D Belcher6 shared
- Ravirajsinh Jadeja3 shared
- Pamela M Martin3 shared
- Kyra J Becker2 shared
- Stephen N. Gomperts2 shared
- Donald A Simone2 shared
- Emanuela Marina Bruscia1 shared
Most similar at Hillhurst Biopharmaceuticals, Inc.
Same institution · by research overlap
- John D Belcher$2,490,337
- Donald A Simone$12,911,965
Others in their field
Top investigators on “Dose”
- Lawrence Corey · Fred Hutchinson Cancer Center$251,944,397
- Sharon A Nachman · Johns Hopkins University$213,337,729
- David Heimbrook · Leidos Biomedical Research, Inc.$146,807,554
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$134,297,561
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$124,321,134
- Peter C Adamson · National Childhood Cancer Foundation$122,197,823
Research focus
DoseOralSafetyToxicologyCarbon MonoxidePreventToxic EffectClinical ResearchBiological AvailabilityImproved OutcomeAnimal ModelPre-ClinicalInhalationClinical TrialsOral AdministrationDrug KineticsLiteratureHemoglobinIn VivoPharmaceutical PreparationsGasesFormulationModalityInflammation
Grant awards (29)
HBI-002 to Prevent Vaso-Occlusive Crises in Sickle Cell Disease$999,718
R44 · FY2025 · HL · contact PI
HBI-002 to Treat Diabetic Retinopathy$961,240
R44 · FY2025 · EY · contact PI
HBI-002 to Prevent Vaso-Occlusive Crises in Sickle Cell Disease$999,898
R44 · FY2024 · HL · contact PI
HBI-002 to Treat Diabetic Retinopathy$950,200
R44 · FY2024 · EY · contact PI
Oral N2O Therapy in Treating Acute Vaso-Occlusive Pain in Sickle Cell Disease$728,111
UH3 · FY2024 · NS · contact PI
HBI-002 for Cystic Fibrosis$299,975
R41 · FY2024 · HL · contact PI
HBI-002 to Prevent Vaso-Occlusive Crises in Sickle Cell Disease$999,578
R44 · FY2023 · HL · contact PI
Low Dose Oral Carbon Monoxide Therapeutic for Virus-Induced Lung Injury$299,894
R41 · FY2023 · AI · contact PI
Oral N2O Therapy in Treating Acute Vaso-Occlusive Pain in Sickle Cell Disease$2,111,258
UG3 · FY2022 · NS · contact PI
Low Dose Oral Carbon Monoxide Therapeutic for Virus-Induced Lung Injury$299,894
R41 · FY2022 · AI · contact PI
HBI-002 to Treat Parkinsonâs Disease$180,754
R41 · FY2022 · NS · contact PI
HBI-002 to Treat Parkinsonâs Disease$453,158
R41 · FY2021 · NS · contact PI
HBI-002 to Treat Diabetic Retinopathy$299,899
R41 · FY2021 · EY · contact PI
HBI-002 to Prevent Anthracycline-Related Cardiotoxicity$76,850
R41 · FY2021 · HL · contact PI
HBI-002 to Treat Ulcerative Colitis$75,058
R41 · FY2021 · DK · contact PI
HBI-002 to Prevent Anthracycline-Related Cardiotoxicity$16,896
R41 · FY2021 · HL · contact PI
Laboratory training and experience for an undergraduate$5,778
R41 · FY2021 · HL · contact PI
HBI-002 to Prevent Anthracycline-Related Cardiotoxicity$222,338
R41 · FY2020 · HL · contact PI
HBI-002 to Treat Ulcerative Colitis$219,112
R41 · FY2020 · DK · contact PI
HBI-002 to Prevent Vaso-Occlusive Crises in Sickle Cell Disease$702,410
R44 · FY2019 · HL · contact PI
HBI-002 to Treat Traumatic Injury$56,476
R43 · FY2019 · GM · contact PI
HBI-002 to Prevent Vaso-Occlusive Crises in Sickle Cell Disease$1,270,298
R44 · FY2018 · HL · contact PI
HBI-002 to Treat Traumatic Injury$168,464
R43 · FY2018 · GM · contact PI
HBI-002 to Treat Delayed Graft Function in Kidney Transplant$635,033
R44 · FY2017 · DK · contact PI
Oral Carbon Monoxide Therapeutic to Prevent Vaso-Occlusive Crises in Sickle Cell Disease$41,551
R43 · FY2017 · HL · contact PI
HBI-002 to Treat Delayed Graft Function in Kidney Transplant$862,618
R44 · FY2016 · DK · contact PI
Oral Carbon Monoxide Therapeutic to Prevent Vaso-Occlusive Crises in Sickle Cell Disease$258,257
R43 · FY2016 · HL · contact PI
Role of HBI-002, an orally administered gasotransmitter, in ischemic stroke$223,821
R43 · FY2016 · NS · contact PI
Role of HBI-002, an orally administered gasotransmitter, in ischemic stroke$475,519
R43 · FY2015 · NS · contact PI